SANTOLINA has embellished the coat of arms of the town Shymkent since the 21of April 1909.
Santonin is a drug which was widely used in the past to expel parasitic worms from the body, by either killing or stunning them. Nowadays Santonin is no longer registered as a drug in most countries. (3 S ,3a S ,5a S ,9b S )-3,5a,9-trimethyl-3a,5,5a,9b-tetrahydronaphtho[1,2- b ]furan-2,8(3 H ,4 H )-dione
Impetuously developing company , equipped with modern abroad equipment , having new modern technologies in the system of operating production and in marketing VISION
Health is the base of any person's happiness . Using the best technologies, the best raw materials and the best specialists we produce effective drugs of high quality at acceptable prices for strengthening people's health and improving life quality in order to give a person an opportunity to feel better , to do more and to live longer . MISSION
<ul><li>20 hectare area for the main and auxiliary production </li></ul><ul><li>spare areas for further development </li></ul><ul><li>the necessary communications </li></ul><ul><li>own boiler - house and chink </li></ul><ul><li>5 main workshops </li></ul><ul><li>research laboratory </li></ul>PRODUCTION BASE
200 denominations of generic and original remedies in the form of capsules, tablets, injection solutions in ampoules, syrups, infusions, oil, water and alcohol solutions of 24 pharmacological groups. PRODUCT PORTFOLIO
over 50% of domestic drug production in Kazakhstan Market share
$ 85 million investment is only the "first phase"
compliance with good manufacturing practice ( GMP ) standards
access to over 300 products already in Polpharma's portfolio, and 400 products being developed - mainly in the gastrological, neurological and cardiology therapeutic areas - as well as oncology and biotech drugs .
KhimPharm gains the higher level of competitive advantage.
STRENGTHS <ul><li>long 100-years history </li></ul><ul><li>high developed production base </li></ul><ul><li>broad product mix </li></ul><ul><li>experienced and professional specialists </li></ul><ul><li>high market share </li></ul>
<ul><li>Access to investments </li></ul><ul><li>State program </li></ul><ul><li>State procurement </li></ul><ul><li>Custom Union </li></ul><ul><li>Good manufacturing practice ( GMP ) standards so it can enter to international market </li></ul><ul><li>The advanced training for personnel </li></ul>
State program for the development of the pharmaceutical industry for 2010-2014 operating in Kazakhstan: in 2014, Kazakhstan’s production of medicines will cover at least 50% of its own market.
SK-Pharmatsiya LLP is a single centralized distributor for supplying pharmaceuticals to State health institutions . The share of pharmaceuticals bought through the single distributor system will gradually increase, reaching 70-80% by 2012.
<ul><li>as of 2014, customs fees for pharmaceutical imports from third countries will be increased first to 5% and then in 2015 to 10%. </li></ul><ul><li>In 2012, Kazakhstan, Belarus, and Russia will adopt documents on mutual recognition of medicine registration </li></ul>CUSTOM UNION
Leverage ratios: Items Years 2006 2007 2008 2009 2010 Financial leverage ratio (Debt/equity) 1,40 1,27 0,84 0,73 0,35
Based on everything I know about this company and its strategies, the industry and the competitors, and the external factors that will influence the company in the future, do I think this company is worth investing in for the long term ? YES . CONCLUSION